The tubarial salivary glands: A potential new organ at risk for radiotherapy
Under a Creative Commons license
open access
Highlights
- •
PSMA PET/CT indicated a previously unnoticed paired nasopharyngeal macroscopic salivary gland.
- •
Presence of paired mucous glands was confirmed in 100 consecutive patients and cadaver histology.
- •
In 723 patients, the radiotherapy dose to this area was associated with xerostomia and dysphagia.
- •
We propose to name these newly identified macroscopic glands the “tubarial glands”.
- •
Sparing these glands in radiotherapy provides an opportunity to improve quality of life.
Abstract
Introduction
The presence of previously unnoticed bilateral macroscopic salivary gland locations in the human nasopharynx was suspected after visualization by positron emission tomography/computed tomography with prostate-specific membrane antigen ligands (PSMA PET/CT). We aimed to elucidate the characteristics of this unknown entity and its potential clinical implications for radiotherapy.
Materials and methods
The presence and configuration of the PSMA-positive area was evaluated in a retrospective cohort of consecutively scanned patients with prostate or urethral gland cancer (n = 100). Morphological and histological characteristics were assessed in a human cadaver study (n = 2). The effect of radiotherapy (RT) on salivation and swallowing was retrospectively investigated using prospectively collected clinical data from a cohort of head-neck cancer patients (n = 723). With multivariable logistic regression analysis, the association between radiotherapy (RT) dose and xerostomia or dysphagia was evaluated.
Results
All 100 patients demonstrated a demarcated bilateral PSMA-positive area (average length 4 cm). Histology and 3D reconstruction confirmed the presence of PSMA-expressing, predominantly mucous glands with multiple draining ducts, predominantly near the torus tubarius. In the head-neck cancer patients, the mean RT dose to the gland area was significantly associated with physician-rated post-treatment xerostomia and dysphagia ≥ grade 2 at 12 months (0.019/gy, 95%CI 0.005–0.033, p = .007; 0.016/gy, 95%CI 0.001–0.031, p = .036). Follow-up at 24 months had similar results.
Conclusion
The human body contains a pair of previously overlooked and clinically relevant macroscopic salivary gland locations, for which we propose the name tubarial glands. Sparing these glands in patients receiving RT may provide an opportunity to improve their quality of life.
Keywords
Tubarial glands
Salivary glands
Radiation toxicity
Radiotherapy
Head and neck cancer
PSMA PET/CT
Cited by (0)
© 2020 The Authors. Published by Elsevier B.V.